Artal Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Artal Group’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-256,400	Closed	-$315K	–	126
2019 Q1	$315K	Hold	256,400	–	–	0.01%	103
2018 Q4	$215K	Hold	256,400	–	–	0.01%	104
2018 Q3	$759K	Hold	256,400	–	–	0.02%	103
2018 Q2	$944K	Hold	256,400	–	–	0.02%	98
2018 Q1	$897K	Hold	256,400	–	–	0.01%	106
2017 Q4	$800K	Hold	256,400	–	–	0.01%	116
2017 Q3	$1.8M	Hold	256,400	–	–	0.03%	97
2017 Q2	$2.37M	Hold	256,400	–	–	0.04%	91
2017 Q1	$2.75M	Hold	256,400	–	–	0.06%	76
2016 Q4	$2.16M	Buy	+256,400	New	+$2.27M	0.05%	77

Other funds holding NVLN

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Artal Group's NVLN Position: Q2 2019 in Review

Artal Group sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2019, closing a stake of 256,400 shares — an estimated $315K sold.

Artal Group first reported a position in NVLN in Q4 2016 and held it in 10 quarters. The position peaked at $2.75M in Q1 2017. 35 funds tracked by Wall St. Rank hold NVLN as of Q2 2019.

Artal Group reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2019 after selling out during the quarter.
Artal Group sold 256,400 Novelion Therapeutics Inc. Common Shares shares in Q2 2019, an estimated $315K.
Artal Group first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 10 quarters.
Artal Group's Novelion Therapeutics Inc. Common Shares position peaked at $2.75M in Q1 2017.
35 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2019.

Based on Artal Group's 13F filing for Q2 2019, filed 9 Aug 2019.